P690: Changes of intestinal microbiota in patients with inflammatory bowel diseasesECCO'21 Virtual
2021
DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
ECCO'20 Vienna
2020
DOP03 The impact of elemental diet on the human gut microbial structure and intestinal metabolites
ECCO'20 Vienna
2020
DOP04 Matching between donors and patients in faecal microbiota transplantation is important for long-term maintenance on ulcerative colitis
ECCO'20 Vienna
2020
DOP06 Non-invasive identification of adherent-invasive E. coli in patients with Crohn’s disease
ECCO'20 Vienna
2020
DOP07 Long-term results of 4.5 years of faecal microbiota transplantation for treatment of refractory ulcerative colitis
ECCO'20 Vienna
2020
DOP08 Deep remission in paediatric Crohn’s disease is associated with increased abundance of dialister species and increased valerate
ECCO'20 Vienna
2020
DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy
ECCO'20 Vienna
2020
DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease
ECCO'20 Vienna
2020
DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension
ECCO'20 Vienna
2020
DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
ECCO'20 Vienna
2020
DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
ECCO'20 Vienna
2020
DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease
ECCO'20 Vienna
2020
DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2
ECCO'20 Vienna
2020
DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
ECCO'20 Vienna
2020